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a  b  s  t  r  a  c  t
Background:  Patients  with  severe  viral  pneumonia  are  likely  to receive  high-dose  immunomodulatory
drugs  to  prevent  clinical  worsening.  Aspergillus  species  have  been  described  as frequent  secondary  pneu-
monia agents  in severely  ill influenza  patients  receiving  steroids.  COVID-19  patients  admitted  to Intensive
Care  Unit  (ICU)  are receiving  steroids  as  part  of  their  treatment  and  they  share  clinical  characteristics  with
other patients  with  severe  viral  pneumonias.  COVID-19  patients  receiving  steroids  should  be  considered
a  putative  risk  group  of  invasive  aspergillosis.
Case  report:  We  are  reporting  a  SARS-CoV-2/Aspergillus  section  Fumigati  coinfection  in  an  elderly  intu-
bated  patient  with  a history  of  pulmonary  embolism  treated  with  corticosteroids.  The  diagnosis  was  made
following  the  ad hoc  definitions  described  for patients  admitted  to ICU with  severe  influenza,  including
clinical  criteria  (fever  for 3  days  refractory  to the  appropriate  antibiotic  therapy,  dyspnea,  pleural  fric-
tion rub,  worsening  of  respiratory  status  despite  antibiotic  therapy  and  need  of  ventilator  support),  a
radiological  criterion  (pulmonary  infiltrate)  and  a  mycological  criterion  (several  positive  galactomannan
tests  on  serum  with  ratio  ≥0.5).  In addition,  Aspergillus  section  Fumigati  DNA was  found  in serum  and
blood  samples.  These  tests  were  positive  4 weeks  after  the  patient  was  admitted  to  the  ICU.  The  patient
received  voriconazole  and after  two  month  in  ICU  his  respiratory  status  improved;  he  was  discharged
after  6 weeks  of  antifungal  treatment.
Conclusions:  Severely  ill COVID-19  patients  would  be considered  a new  aspergillosis  risk group.  Galac-
tomannan  and  Aspergillus  DNA  detection  would  be useful  methods  for  Aspergillus  infection  diagnosis  as
they  allow  avoiding  the  biosafety  issues  related  to these  patients.
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r  e  s  u  m  e  n
Antecedentes:  Los  pacientes  con  neumonía  viral  grave  reciben  altas  dosis  de fármacos  inmunomodu-
ladores  para  prevenir  el empeoramiento  clínico.  Los  pacientes  con influenza  grave  que reciben  esteroides
tienen  neumonías  secundarias  causadas  por  Aspergillus  con  una  frecuencia  relativamente  alta.  Los
pacientes  con COVID-19  ingresados  en  la  unidad  de cuidados  intensivos  (UCI) reciben  dicha  medicación
como  parte  de  su  tratamiento,  y comparten  con otro  tipo  de  pacientes  muchas  de  las  características  clíni-
cas de  otras  neumonías  virales  graves.  Estos  pacientes  deberían  considerarse  como  un  grupo  de  riesgo
de aspergilosis  invasiva.
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Caso  clínico:  Se  presenta  un  caso  de  coinfección  por  SARS-CoV-2  y Aspergillus  de  la  sección  Fumigati
en un  paciente  intubado  de  edad  avanzada  con  antecedentes  de  embolia  pulmonar  y  tratado  con  cor-
ticosteroides.  El diagnóstico  siguió  las  definiciones  ad hoc  descritas  para  pacientes  ingresados  en  la
UCI  con  gripe  grave.  El  paciente  cumplía  varios  criterios  clínicos  (fiebre  durante  3  días  refractaria  al
tratamiento  antibiótico  apropiado,  disnea,  fricción  pleural,  empeoramiento  del estado  respiratorio  a  pesar
del  tratamiento  antibiótico  y  la  necesidad  de  soporte  respiratorio),  el criterio  radiológico  (infiltrado  pul-
monar)  y un  criterio  micológico  (test  de  galactomanano  positivo  en  suero,  (ratio  ≥ 0,5).  Además,  se  detectó
ADN  de  Aspergillus  de  la  sección  Fumigati  en  muestras  de  suero  y sangre  del  paciente.  Estas pruebas  fueron
positivas  4 semanas  después  de que  el paciente  ingresara  en  la  UCI.  El  paciente  recibió  tratamiento  con
voriconazol,  y  después  de  2  meses  en  la  UCI  mejoró  su estado  pulmonar;  fue  dado  de  alta  después  de  6
semanas  de  tratamiento  antifúngico.
Conclusiones:  Los  pacientes  gravemente  enfermos  con  COVID-19  deberían  considerarse  un  nuevo  grupo
de  riesgo  para  la  aspergilosis.  La  detección  de  galactomanano  y ADN  de  Aspergillus  son  métodos  útiles para
el  diagnóstico  de  infección  por  este  hongo  al evitar  los  problemas  de bioseguridad  en  estos  pacientes.











































Intensive care admission is needed in 5% of the patients suffering
evere acute respiratory syndrome caused by the SARS-CoV-
.9 Viral replication, together with the release of inflammatory
ytokines (cytokine storm), produce a severe lung damage.6
egardless of their debatable usefulness, corticosteroids are usu-
lly administered in patients with severe viral pneumonia. In this
cenario, the risk of developing opportunistic infections as inva-
ive aspergillosis is high.2 This fact was reported with influenza (B
nd H1N1) where invasive aspergillosis is an early and frequent
omplication (reaching 19% incidence) and earlier with SARS-Cov
n 2003.3,7 Considering the similarities between these viral infec-
ions and COVID-19, it is essential to establish whether SARS-CoV-2
everely ill patients treated with corticosteroids constitute a new
isk group for invasive aspergillosis.
This work reports a case of a 73-year-old male with a history
f pulmonary embolism (2004) and thrombophlebitis. He traveled
o Europe (Austria and Spain) on December 2019 and returned to
rgentina on March 14th 2020. He was admitted to Adventista del
lata Sanatorium on March 21st 2020 due to symptoms that began
 days earlier, consisting of low fever (37.5 ◦C), fatigue, weakness,
ausea and vomiting. He denied any respiratory symptom (cough,
yspnea, etc.). A nasopharyngeal swabbing was performed to carry
ut diagnostic tests for influenza A, B and COVID-19. On March 26th
ARS-CoV-2 viral RNA was detected by real-time-PCR.
A CT-scan was performed on March 23rd: bilateral “ground
lass” opacities with a predominantly peripheral and multilobar
ocation were shown. The largest infiltrate was found in the base
f the right lung with a tendency to consolidate. In the left lung,
pacities were located mainly in the upper lobe, and bilateral
leural thickenings were also reported. These findings suggested
typical pneumonia (Fig. 1). The patient was receiving enoxaparin,
cetaminophen and metoclopramide since his admission. After
he CT scan, an antibacterial treatment was added (500 mg/12 h
larithromycin and 1.5 g/6 h ampicillin + sulbactam, AMS). Later
n, and after the real-time-PCR results, clarithromycin was dis-
ontinued and hydroxychloroquine (400 mg/12 h), azithromycin
500 mg/day) and methylprednisolone (1 g) were added. Oxygen
aturation decreased from 95% (March 22nd) to 88% (March 28th)
espite receiving supplemental O2 (14 l using a reservoir bag oxy-
en mask).
On March 28th the patient was referred to the Intensive Care
nit (ICU) where he received mechanical ventilation assistancePlease cite this article in press as: Sasoni N, et al. SARS-CoV-2 and A
patient treated with corticosteroids. Rev Iberoam Micol. 2021. https:/
ith orotracheal intubation (Kirby index = 80). On April 2nd
iperacillin tazobactam (PTZ) (4.5 mg/6 h) was added after the
solation of Pseudomonas aeruginosa in a tracheal aspirate. On
pril 16th the patient was  extubated (he stayed with a reservoirreservados.
bag oxygen mask) but two  days later he was intubated again due
to failure in ventilation and fibrillation. He received PTZ again
(4.5 mg/6 h for 48 h), which was  later changed to trimethoprim
sulfamethoxazole (TMS) (160/800 mg/12 h). On April 20th a new
treatment with vancomycin (1 g/12 h, 5 days, due to Staphylococ-
cus aureus isolation in miniBAL) and fluconazole (200 mg/12 h) as
empirical treatment, was started.
On April 24th, the first galactomannan quantification in serum
was performed by using PlateliaTM-Aspergillus-EIA (BioRad) and
SŌNATM-Aspergillus-GM-LFA (Immy) at the Micología y Diagnóstico
Molecular Laboratory. New samples were sent on April 28th, and
May  1st, 3rd, 5th and 10th. The obtained OD ratios were 1.8, 1.3, 0.8,
0.5, 0.4, and 0.3, and LFAs were positive for the first 3 serum sam-
ples. Platelia EIA tests were repeated on serum samples stored for
24 h at −20 ◦C to confirm the results. Nested PCR based on panfungal
18S-rDNA amplification coupled to an Aspergillus section Fumigati
specific amplification4 were performed on the same samples. Those
molecular tests were positive in the first three samples (Fig. 1).
After the first positive galactomannan/PCR assay, 50 mg/day
deoxicholate amphotericin-B were administered for three days (it
was, along with fluconazole, the only available antifungal agent
at the institution). Then, the antifungal treatment was  shifted
to voriconazole (IV 6 mg/kg/12 h the first day, followed by IV
4 mg/kg/12 h that was shifted to oral voriconazole 200 mg/12 h)
and TMS  was  discontinued. In the meanwhile, the patient was
reintubated (orotracheal) and two days later a percutaneous
tracheostomy was performed. No mycological cultures were per-
formed before starting the antifungal treatment (the culture was
performed with a sample obtained on May  3rd, when the results
of galactomanan and PCR were already negative). On April 30th
the result of SARS-CoV-2 RT-PCR was negative, and the same result
was obtained for the second time on May  4th. On May  10th, the
patient began to breathe without assistance for several hours. Since
then, his respiratory status improved markedly, he had no fever and
leukocytes count was  lower than 11,000 cells/ml. Oral voriconazole
treatment for 6 weeks was  prescribed. On May  26th and on June
2nd, he was  discharged from ICU and from the hospital, respec-
tively.
This case accomplishes the ad hoc definitions described for
patients admitted to the ICU with severe influenza, including
several clinical criteria, and radiological and mycological crite-
ria. In addition, Aspergillus section Fumigati DNA was detected inspergillus section Fumigati coinfection in an immunocompetent
/doi.org/10.1016/j.riam.2020.11.001
serum and blood samples, a result that fulfills the EORCT/MSGER
definitions for the diagnosis of probable invasive aspergillosis.1
These evidences were obtained one month after the patient’s
ICU admission. After receiving the proper antifungal treatment,
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Fig. 1. (A–C) Chest X rays showing the evolution of the patient. (D) Gel electrophoresis of nested PCRs: lane M,  molecular weight (1 kb ladder); lane 1, positive control using
h ; lane
( sampl




























et al. Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbeuman serum spiked with 10 ng of Aspergillus fumigatus LMDM-31 DNA as sample
743  pb band); lane 5, negative nested PCR result using DNA extracted from the 4th 
M-LFA (Immy) showing positive bands in the samples of the days April 28th and M
sing  PlateliaTM Aspergillus EIA (BioRad).
atient’s respiratory function improved. As a conclusion we
an state that aspergillosis should be considered a probable
omorbidity in seriously ill patients with COVID-19 receiving corti-
osteroids. Furthermore, screening the presence of galactomannan
n serum could be carried out routinely in these patients (tak-
ng into account, anyway, the known limitations of this technique
n non-immunosuppressed patients), especially considering that
OVID-19/Aspergillus coinfection has been recently reported.5,8
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s 2–4, nested PCR results using DNA obtained from the 3 first samples submitted
e (May 3rd); lane 6, nested PCR blank. (E) Results obtained with SŌNATM Aspergillus
t (coinciding with the results obtained with the nested PCR). (F) OD  ratio evolution
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